Brazilian pharmaceutical firm Biolab Pharma has collaborated with the Government of Ontario, Canada, to open its first international research development and innovation (RD&I) facility in the province.

The new 13,000ft² RD&I facility, which is part of the firm’s overall C$57.4m ($45.41m) investment, will see a funding of C$2.8m ($2.2m) through the Ontario’s Jobs and Prosperity Fund.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Biolab Pharma CEO Cleiton de Castro Marque said: “We are pleased to partner with the Ontario government on this exciting initiative as we expand our operations internationally.

“Our new facility will help us sharpen our competitive edge and better serve our customers by continually improving and creating innovative products.”

The firm is also planning for new equipment and special software to improve its research capabilities, which could allow development and commercialisation of new products in North America and Europe.

Planned to open in Mississauga city, the facility is anticipated to be complete by December 2020 and is expected to create new life sciences jobs, aiding economic growth of Ontario.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Ontario Finance Minister Charles Sousa said: “Through the Jobs and Prosperity Fund alone, businesses have created or retained more than 35,000 jobs, including 40 announced today at Biolab Pharma.

“These partnerships contribute to the strong and sustained growth of the Ontario economy, with over 794,500 net new jobs created since the recession.”

With more than 50% of Canada’s total life sciences economic activity, Ontario’s life sciences sector employs approximately 60,000 people.

Biolab Pharma develops, manufactures and commercialises prescription medicines, with a primary focus on drugs for cardiology and dermatology.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact